Phaseline

Companies › Vittoria Biotherapeutics

Vittoria Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Senza5 CART5
CD5-deleted CAR-T cell therapy targeting CD5-positive T cell lymphomas
CD5Phase 1T Cell Non-Hodgkin LymphomaAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06420089Senza5 CART5Phase 1T Cell Non-Hodgkin LymphomaOncologyAug 2028

Targets

CD5 (1)

Companies with the same targets

March Biosciences Chongqing Precision Biotech Beijing Biotech

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.